Literature DB >> 33899933

Associations between T cell infiltration, T cell receptor clonality, histology and recurrence in renal cell carcinoma.

Moran Gadot1, Mordechay Gal2, Paula Dobosz3, Zohar Dotan4,5, Jacob Ramon4,5, Raanan Berger1,5, Dror Avni5,6, Eduard Fridman5,7, Raya Leibowitz5,8.   

Abstract

Renal cell carcinoma (RCC) is comprised of clear-cell (ccRCC) and non-clear-cell (nccRCC) tumors. Despite definitive surgical resection in localized disease, recurrence often occurs. A commercial method based on a multiplex polymerase chain reaction (PCR) assay exclusively targets rearranged T cell receptor (TCR) genes to generate high-throughput sequencing-based data, allowing characterization of the immune repertoire within tumors. In this study we performed a retrospective analysis on archived tumor samples from patients with recurring versus non-recurring T3 ccRCC and on samples from early nccRCC versus ccRCC. Following genomic DNA extraction and multiplex PCR, the fraction of T cells within tumors, the number of unique receptors ('richness') and their relative abundances ('clonality') were calculated. Statistical significance and correlations were calculated using Student's t-test and Spearman's rho, respectively. Average fraction and clonality of T cells in tumors from non-recurring patients was 2.5- and 4.3-fold higher than in recurring patients (P = 0.025 and P = 0.043, respectively). A significant positive correlation was found between T cell fraction and clonality (Spearman's rho = 0.78, P = 0.008). The average fraction of T cells in ccRCC tumors was 2.8-fold higher than in nccRCC tumors (P = 0.015). Clonality and estimated richness were similar between ccRCC and nccRCC tumors. In summary, recurrence of ccRCC is associated with a lower fraction and clonality of T cells within tumors; nccRCC tumors are more 'deserted' than ccRCC, but similar in their ability to generate a clonal T cell repertoire. Our work suggests associations between the characteristics of T cell infiltrate, histology and tumor recurrence.
© 2021 British Society for Immunology.

Entities:  

Keywords:  RCC; TCR; TIL; clonality; repertoire

Mesh:

Substances:

Year:  2021        PMID: 33899933      PMCID: PMC8274198          DOI: 10.1111/cei.13608

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   5.732


  24 in total

1.  Tumor-Infiltrating and Peripheral Blood T-cell Immunophenotypes Predict Early Relapse in Localized Clear Cell Renal Cell Carcinoma.

Authors:  Nicolas A Giraldo; Etienne Becht; Yann Vano; Florent Petitprez; Laetitia Lacroix; Pierre Validire; Rafael Sanchez-Salas; Alexandre Ingels; Stephane Oudard; Audrey Moatti; Benedicte Buttard; Sarah Bourass; Claire Germain; Xavier Cathelineau; Wolf H Fridman; Catherine Sautès-Fridman
Journal:  Clin Cancer Res       Date:  2017-02-17       Impact factor: 12.531

Review 2.  Grading of renal cell carcinoma.

Authors:  Brett Delahunt; John N Eble; Lars Egevad; Hemamali Samaratunga
Journal:  Histopathology       Date:  2019-01       Impact factor: 5.087

3.  Prognostic indicators for renal cell carcinoma: a multivariate analysis of 643 patients using the revised 1997 TNM staging criteria.

Authors:  K H Tsui; O Shvarts; R B Smith; R A Figlin; J B deKernion; A Belldegrun
Journal:  J Urol       Date:  2000-04       Impact factor: 7.450

Review 4.  Systemic Treatment of Metastatic Clear Cell Renal Cell Carcinoma in 2018: Current Paradigms, Use of Immunotherapy, and Future Directions.

Authors:  Aly-Khan A Lalani; Bradley A McGregor; Laurence Albiges; Toni K Choueiri; Robert Motzer; Thomas Powles; Christopher Wood; Axel Bex
Journal:  Eur Urol       Date:  2018-10-13       Impact factor: 20.096

Review 5.  Non-Clear Cell Renal Cell Carcinoma - Pathology and Treatment Options.

Authors:  Marit Ahrens; Sebastian Scheich; Arndt Hartmann; Lothar Bergmann
Journal:  Oncol Res Treat       Date:  2019-02-23       Impact factor: 2.825

6.  Risk group assessment and clinical outcome algorithm to predict the natural history of patients with surgically resected renal cell carcinoma.

Authors:  Amnon Zisman; Allan J Pantuck; Jeffery Wieder; Debby H Chao; Fredrick Dorey; Jonathan W Said; Jean B deKernion; Robert A Figlin; Arie S Belldegrun
Journal:  J Clin Oncol       Date:  2002-12-01       Impact factor: 44.544

Review 7.  The 2016 WHO Classification of Tumours of the Urinary System and Male Genital Organs-Part A: Renal, Penile, and Testicular Tumours.

Authors:  Holger Moch; Antonio L Cubilla; Peter A Humphrey; Victor E Reuter; Thomas M Ulbright
Journal:  Eur Urol       Date:  2016-02-28       Impact factor: 20.096

8.  Tumor immune microenvironment characterization in clear cell renal cell carcinoma identifies prognostic and immunotherapeutically relevant messenger RNA signatures.

Authors:  Yasin Şenbabaoğlu; Ron S Gejman; Andrew G Winer; Ming Liu; Eliezer M Van Allen; Guillermo de Velasco; Diana Miao; Irina Ostrovnaya; Esther Drill; Augustin Luna; Nils Weinhold; William Lee; Brandon J Manley; Danny N Khalil; Samuel D Kaffenberger; Yingbei Chen; Ludmila Danilova; Martin H Voss; Jonathan A Coleman; Paul Russo; Victor E Reuter; Timothy A Chan; Emily H Cheng; David A Scheinberg; Ming O Li; Toni K Choueiri; James J Hsieh; Chris Sander; A Ari Hakimi
Journal:  Genome Biol       Date:  2016-11-17       Impact factor: 13.583

Review 9.  Immune Checkpoint Inhibitors in the Treatment of Renal Cancer: Current State and Future Perspective.

Authors:  Daniele Lavacchi; Elisa Pellegrini; Valeria Emma Palmieri; Laura Doni; Marinella Micol Mela; Fabrizio Di Maida; Amedeo Amedei; Serena Pillozzi; Marco Carini; Lorenzo Antonuzzo
Journal:  Int J Mol Sci       Date:  2020-06-30       Impact factor: 5.923

10.  Renal Cell Carcinoma (RCC) Tumors Display Large Expansion of Double Positive (DP) CD4+CD8+ T Cells With Expression of Exhaustion Markers.

Authors:  Laurence C Menard; Paul Fischer; Bijal Kakrecha; Peter S Linsley; Erik Wambre; Maochang C Liu; Blake J Rust; Deborah Lee; Becky Penhallow; Nataly Manjarrez Orduno; Steven G Nadler
Journal:  Front Immunol       Date:  2018-11-26       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.